Rachid Izzar - 12 Feb 2022 Form 4 Insider Report for BIOGEN INC. (BIIB)

Role: Head of Alzheimer's Disease
Signature: /s/ Wendell Taylor, attorney-in-fact for Rachid Izzar
Issuer symbol: BIIB
Transactions as of: 12 Feb 2022
Transactions value $: -$26,180
Form type: 4
Filing time: 15 Feb 2022, 15:14:45 UTC
Previous filing: 14 Feb 2022
Next filing: 23 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BIIB	Common Stock	Options Exercise	$0	+351	+31.74%	$0.00	1.46K	12 Feb 2022	Direct
transaction	BIIB	Common Stock	Tax liability	-$26.2K	-122	-8.37%	$214.59	1.34K	12 Feb 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BIIB	Restricted Stock Unit	Options Exercise	$0	-351	-17.48%	$0.00	1.66K	12 Feb 2022	Common Stock	351	$0.00	Direct	F1
transaction	BIIB	Restricted Stock Unit	Other	$0	-651	-39.29%	$0.00	1.01K	12 Feb 2022	Common Stock	651	$0.00	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F2	This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.
F3	This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).